Boston Scientific

TriMed Staff | | Cardiovascular Business | Patient Care
Boston Scientific (Booth 814) is highlighting various lectures, presentations and analyses of the recently released results of the SYNTAX trial.

The SYNTAX trial aims to explore the interface between treatment with CABG and PCI in patients with three-vessel and left main stem disease, comparing CABG using contemporary techniques and PCI using Boston Scientific’s Taxus drug eluting stents.

The majority of the lectures and presentations will take place on Tuesday, Oct, 14, when from 2:00-6:00, an entire session will be dedicated to the “Revascularization for Left Main and Triple Vessel Disease: Focus on SYNTAX” in room 147AB.

TriMed Staff

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.